Filtered By:
Specialty: Hematology
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 18 results found since Jan 2013.

The potential role of micro-RNA 125b-5p level in predicting outcome from thrombolytic therapy in patients with acute ischemic stroke
AbstractSeveral studies highlighted a significant role of specific miRNA as diagnostic and prognostic biomarkers for acute ischemic stroke. The aim of this work was to study micro-RNA 125b-5p level in patients with acute ischemic stroke in relation to stroke etiology, risk factors, severity and outcome. This case –control study was conducted on 40 patients with acute ischemic stroke eligible for receiving rt-PA and 40 age and sex matched healthy controls, Patients were submitted to neurological and radiological assessment. Functional outcome after 3 months was assessed using the modified Rankin Scale (mRS ). Plasma micr...
Source: Journal of Thrombosis and Thrombolysis - June 8, 2023 Category: Hematology Source Type: research

Fibrinolysis: Strategies to enhance the treatment of acute ischemic stroke.
This article is protected by copyright. All rights reserved. PMID: 29953716 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 28, 2018 Category: Hematology Authors: Henderson SJ, Weitz JI, Kim PY Tags: J Thromb Haemost Source Type: research

Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke
Thrombolytic therapy using tissue plasminogen activator (tPA) in acute stroke is associated with increased risks of cerebral hemorrhagic transformation and angioedema. Although plasma kallikrein (PKal) has been implicated in contributing to both hematoma expansion and thrombosis in stroke, its role in the complications associated with the therapeutic use of tPA in stroke is not yet available. We investigated the effects of tPA on plasma prekallikrein (PPK) activation and the role of PKal on cerebral outcomes in a murine thrombotic stroke model treated with tPA. We show that tPA increases PKal activity in vitro in both muri...
Source: Blood - April 20, 2017 Category: Hematology Authors: Simao, F., Ustunkaya, T., Clermont, A. C., Feener, E. P. Tags: Thrombosis and Hemostasis Source Type: research

Red Blood Cell Distribution Width Is an Independent Predictor of Outcome in Patients Undergoing Thrombolysis for Ischemic Stroke
Semin Thromb Hemost DOI: 10.1055/s-0036-1592165An appropriate and timely management, including early diagnosis and accurate prognostication, is the mainstay for managed care of patients with acute ischemic stroke. Since red blood cell distribution width (RDW) was found to be an independent predictor of clinical outcomes in patients with thrombotic disorders, we designed a retrospective observational study to investigate whether the RDW value may also retain predictive significance in stoke patients undergoing thrombolytic therapy. This retrospective study was based on all patients admitted to the Emergency Department (ED) ...
Source: Seminars in Thrombosis and Hemostasis - November 2, 2016 Category: Hematology Authors: Turcato, Gianni Cappellari, Manuel Follador, Luca Dilda, Alice Bonora, Antonio Zannoni, Massimo Bovo, Chiara Ricci, Giorgio Bovi, Paolo Lippi, Giuseppe Tags: Review Article Source Type: research

Efficacy and safety of thrombolysis for stroke of unknown onset time: a meta-analysis
Abstract Current stroke treatment guidelines exclude unknown onset stroke (UOS) patients from thrombolytic therapy even though several studies have reported significant treatment efficacy and safety. We performed a meta-analysis of relevant studies retrieved by systematic searches of the PubMed, Embase, and Cochrane databases up to December 31, 2013. Dichotomized modified Rankin Scale (mRS) scores 0–1 at 90 days, mRS 0–2 at 90 days, overall mortality, and symptomatic intracranial hemorrhage (sICH) incidence were collected as primary outcome measures. Fixed effects meta-analytical models were used, and betwe...
Source: Journal of Thrombosis and Thrombolysis - October 2, 2014 Category: Hematology Source Type: research

Lack Of Tafi Increases Brain Damage And Microparticle Generation After Thrombolytic Therapy In Ischemic Stroke
Thrombin-activatable fibrinolysis inhibitor (TAFI) plays an important role in coagulation and fibrinolysis. Whereas TAFI deficiency may lead to a haemorrhagic tendency, data from TAFI knockout mice (TAFI−/−) are controversial and no differences have been reported in these animals after ischemic stroke. There are also no data regarding the role of circulating microparticles (MPs) in TAFI−/−.
Source: Thrombosis Research - June 10, 2015 Category: Hematology Authors: Orbe J, Alexandru N, Roncal C, Belzunce M, Bibiot P, Rodriguez JA, Meijers JCM, Georgescu A, Paramo JA Source Type: research

Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke.
PMID: 26864700 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 11, 2016 Category: Hematology Authors: Campello E, Farina F, Spiezia L, Maggiolo S, Palmieri A, Sartorello F, Baracchini C, Simioni P Tags: Thromb Haemost Source Type: research

Predicting a post‐thrombolysis intracerebral hemorrhage: a systematic review
ConclusionsThe development and clinical application of ICH risk scores remains a developing field. Extensive external validation and impact studies are needed to strengthen evidence regarding their utility for improving the selection of ischemic stroke victims for thrombolysis while mitigating risks of complications through post‐thrombolysis ICH.
Source: Journal of Thrombosis and Haemostasis - May 15, 2013 Category: Hematology Authors: J. B. Echouffo‐Tcheugui, M. Woodward, A. P. Kengne Tags: Original Article Source Type: research

Predicting post‐thrombolysis intracerebral hemorrhage: A systematic review
Abstract ObjectivesFear of intracerebral hemorrhage (ICH) is a deterrent to the uptake of thrombolytic therapy, an evidence‐based treatment for acute ischemic stroke. Several characteristics associated with post‐thrombolysis ICH have been identified, but their combined utility for risk stratification has yet to be clarified. We critically examined risk models to predict post‐thrombolysis ICH, and evaluated their potential clinical utility. MethodsMEDLINE (Inception to October 2012) was searched and bibliographies of retrieved articles examined. Inclusion and exclusion criteria of each study were reviewed. Eligible st...
Source: Journal of Thrombosis and Haemostasis - March 7, 2013 Category: Hematology Authors: J B. Echouffo‐Tcheugui, M Woodward, A P Kengne Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta‐analysis
ConclusionMortality in patients treated by thrombolytic therapy for valve prosthesis thrombosis is significantly lower than in patients treated surgically. As we cannot yet ascertain whether this difference is due to the treatment alone, more studies now are necessary to further clarify these findings.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 2, 2014 Category: Hematology Authors: F. M. Castilho, M. R. Sousa, A. L. P. Mendonça, A. L. P. Ribeiro, F. M. Cáceres‐Lóriga Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta-analysis.
CONCLUSION: Mortality in patients treated by thrombolytic therapy for valve prosthesis thrombosis is significantly lower than in patients treated surgically. As we cannot yet ascertain whether this difference is due to the treatment alone, more studies now are necessary to further clarify these findings. This article is protected by copyright. All rights reserved. PMID: 24698327 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 2, 2014 Category: Hematology Authors: Castilho FM, Sousa MR, Mendonça AL, Ribeiro AL, Cáceres-Lóriga FM Tags: J Thromb Haemost Source Type: research

Outcomes and risk factors of perforating and non-perforating middle cerebral artery infarctions after intravenous thrombolysis
AbstractThe clinical symptoms of perforating arteries differ, and responses to intravenous thrombolytic therapy are heterogeneous. Here, we investigated the effect of intravenous thrombolytic therapy and the related factors influencing acute perforating and non-perforating middle cerebral artery infarctions. We analyzed 320 patients with acute middle cerebral artery infarction who received alteplase thrombolysis within 4.5  h of onset at two stroke centers from January 2016 to December 2019. Outcome measures included rates of a favorable functional outcome (modified Rankin Scale scores of 0–2), distribution of modified ...
Source: Journal of Thrombosis and Thrombolysis - January 14, 2022 Category: Hematology Source Type: research

Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs
Thrombolytic therapy is the cornerstone of treatment of acute atherothrombotic ischemic stroke but is associated with brain hemorrhage; antiplatelet therapy has limited efficacy and is still associated with intracranial bleeding. Therefore, new antithrombotic approaches with a better efficacy/safety ratio are required. We have assessed the effect of ALX-0081, a Nanobody against the A1 domain of von Willebrand factor (VWF) that blocks VWF binding to GPIb, of the thrombolytic agent recombinant tissue plasminogen activator (rtPA), and of the GPIIb/IIIa antagonist tirofiban, in a middle cerebral artery (MCA) thrombosis model i...
Source: Blood - June 20, 2013 Category: Hematology Authors: Momi, S., Tantucci, M., Van Roy, M., Ulrichts, H., Ricci, G., Gresele, P. Tags: Platelets and Thrombopoiesis, Thrombosis and Hemostasis Source Type: research

The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model
Reperfusion injury after thrombolytic therapy can have adverse neurologic effects. The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke. However, basic investigations of this combination use remain inadequate. Here, we used an in vivo model to investigate the effects of edaravone on alteplase-induced thrombolysis.
Source: Thrombosis Research - April 13, 2015 Category: Hematology Authors: Tsutomu Yamashita, Takumi Sato, Kumi Sakamoto, Hiromitsu Ishii, Junichiro Yamamoto Tags: Regular article Source Type: research

Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol
Abstract Acute ischemic stroke (AIS) patients receiving non-vitamin-K antagonist oral anticoagulants (NOAC) are commonly excluded from thrombolytic therapy, as interpretation of coagulation tests remains unclear. We aimed to investigate the applicability of a novel institutional protocol for thrombolysis based on current expert recommendations and NOAC specific coagulation assessment. We included hospitalized AIS patients receiving NOAC for at least 24 h and consecutive AIS patients not receiving NOAC into a prospective study. We performed standard coagulation tests and specific tests for dabigatran, rivaroxaban ...
Source: Journal of Thrombosis and Thrombolysis - May 23, 2015 Category: Hematology Source Type: research